Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
| Revenue (TTM) | $47.35B |
| Gross Profit (TTM) | $34.26B |
| EBITDA | $12.83B |
| Operating Margin | 20.00% |
| Return on Equity | 6.58% |
| Return on Assets | 4.67% |
| Revenue/Share (TTM) | $19.52 |
| Book Value | $34.40 |
| Price-to-Book | 1.23 |
| Price-to-Sales (TTM) | 2.17 |
| EV/Revenue | 2.189 |
| EV/EBITDA | 12.16 |
| Quarterly Earnings Growth (YoY) | -11.70% |
| Quarterly Revenue Growth (YoY) | 6.00% |
| Shares Outstanding | $2.39B |
| Float | $2.17B |
| % Insiders | 0.00% |
| % Institutions | 8.88% |
Volatility is currently expanding
The European Commission said on Wednesday it would seek feedback on commitments offered by French pharmaceutical company Sanofi to address concerns that it may have breached competition rules in a flu vaccine marketing campaign.
Sanofi's phase III Baby-COMET study meets all goals for Nexviazyme in infantile-onset Pompe disease, paving the way for a planned U.S. filing in H2 2026.
Availability of the aide-mémoire for Q2 2026 results Paris, France – July 1, 2026. Sanofi announced today the availability of the aide-mémoire for Q2 2026 results on the "Investors" page of sanofi.com: Second quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results.
The European Commission opened on Friday an investigation into whether French drug giant Sanofi breached EU competition rules in a flu vaccine marketing campaign.
Sanofi is reiterated as a compelling buy, trading at a pronounced valuation discount versus pharma peers despite solid results and strategic focus. Dupixent drives 40% of Sanofi's sales and 80% of Q1 incremental growth; management is pursuing lifecycle management to mitigate 2031 U.S. LOE risk. Dupixent concentration is not unique. Management continues to pursue lifecycle management initiatives, including new formulations and a hyaluronidase co-formulation, while planning conservatively under a no-extension scenario.
Sanofi Foundation opens new chapter centered on future generations Paris, June 2 5 , 2026 . The Sanofi Foundation is opening a new chapter with a strengthened commitment to children and young people, particularly those living with serious diseases.
Sanofi wins EU nod for Cenrifki in secondary progressive multiple sclerosis without relapses, while Wayrilz gets Japan nod for immune thrombocytopenia.
The authorization of Cenrifki for the treatment of secondary progressive multiple sclerosis without relapses follows a rejection from U.S. drug regulators.
Sanofi's Wayrilz approved in Japan to treat immune thrombocytopenia Wayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other symptoms ITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of life Paris, June 23, 2026. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization to Wayrilz (rilzabrutinib), a novel oral reversible Bruton's tyrosine kinase inhibitor (BTKi), for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who do not respond sufficiently to other treatments or in whom tolerability is considered to be problematic.
SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.
